Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.05), $0.19 better than the analyst estimate of ($1.24). Revenue for the quarter came in at $8.7 million versus the consensus estimate of $8.09 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.